JP2013515737A - 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法 - Google Patents

精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法 Download PDF

Info

Publication number
JP2013515737A
JP2013515737A JP2012546161A JP2012546161A JP2013515737A JP 2013515737 A JP2013515737 A JP 2013515737A JP 2012546161 A JP2012546161 A JP 2012546161A JP 2012546161 A JP2012546161 A JP 2012546161A JP 2013515737 A JP2013515737 A JP 2013515737A
Authority
JP
Japan
Prior art keywords
pyrrolo
dihydro
trans
dione
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515737A5 (OSRAM
Inventor
デイビッド ピー． リード，
ニール アール． バーンズ，
ジョン シー． ケイン，
クリストファー エー． リー，
ジャン−シェー チェン，
マーティン ピー． レッドモン，
Original Assignee
アークル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アークル インコーポレイテッド filed Critical アークル インコーポレイテッド
Publication of JP2013515737A publication Critical patent/JP2013515737A/ja
Publication of JP2013515737A5 publication Critical patent/JP2013515737A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2012546161A 2009-12-23 2010-12-21 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法 Pending JP2013515737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28956309P 2009-12-23 2009-12-23
US61/289,563 2009-12-23
PCT/US2010/061625 WO2011079142A2 (en) 2009-12-23 2010-12-21 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015198998A Division JP2016041712A (ja) 2009-12-23 2015-10-07 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法

Publications (2)

Publication Number Publication Date
JP2013515737A true JP2013515737A (ja) 2013-05-09
JP2013515737A5 JP2013515737A5 (OSRAM) 2014-02-06

Family

ID=44188284

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546161A Pending JP2013515737A (ja) 2009-12-23 2010-12-21 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
JP2015198998A Pending JP2016041712A (ja) 2009-12-23 2015-10-07 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015198998A Pending JP2016041712A (ja) 2009-12-23 2015-10-07 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法

Country Status (19)

Country Link
US (3) US8552192B2 (OSRAM)
EP (2) EP2515904A4 (OSRAM)
JP (2) JP2013515737A (OSRAM)
KR (2) KR101669707B1 (OSRAM)
CN (2) CN102834097B (OSRAM)
AU (2) AU2010336533B9 (OSRAM)
BR (1) BR112012015656A2 (OSRAM)
CA (1) CA2785503A1 (OSRAM)
CO (1) CO6561823A2 (OSRAM)
HK (1) HK1215025A1 (OSRAM)
MX (1) MX2012007259A (OSRAM)
MY (2) MY169232A (OSRAM)
NZ (2) NZ628087A (OSRAM)
PH (2) PH12012501293A1 (OSRAM)
RU (1) RU2556205C2 (OSRAM)
SG (1) SG181927A1 (OSRAM)
TW (3) TWI506026B (OSRAM)
WO (1) WO2011079142A2 (OSRAM)
ZA (1) ZA201204759B (OSRAM)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518284A (ja) * 2011-07-07 2014-07-28 アーキュール，インコーポレイティド ピロロキノリニル−ピロリジン−２，５−ジオン製剤及びその調製方法及び使用方法
JP2016041712A (ja) * 2009-12-23 2016-03-31 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
JP2020530497A (ja) * 2017-08-11 2020-10-22 アクチュエイト セラピューティクス インク． ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846406T1 (sl) * 2005-02-09 2011-02-28 Arqule Inc Maleimidni derivati, farmacevtski sestavki in postopki za zdravljenje raka
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024513502A (ja) * 2021-04-07 2024-03-25 ユリカ セラピューティクス インコーポレイテッド Ｕｒａｔ１阻害剤、医薬組成物及びその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229026A1 (en) * 1999-12-16 2003-12-11 Al-Awar Rima Salim Agents and methods for the treatment of proliferative diseases
JP2008530026A (ja) * 2005-02-09 2008-08-07 アーキュール，インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
JP2010530884A (ja) * 2007-06-22 2010-09-16 アークル インコーポレイテッド 癌の治療のための組成物および方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4128015A1 (de) * 1991-08-23 1993-02-25 Kali Chemie Pharma Gmbh 1,7-anellierte 2-(piperazinoalkyl)indol-derivate sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindugnen enthaltende arzneimittel
US5760237A (en) * 1995-08-25 1998-06-02 California Institute Of Technology Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
WO2004013069A1 (en) * 2002-07-31 2004-02-12 Firmenich Sa A process for the optical resolution of a precursor of sclareolide
EP1786772A1 (en) * 2004-09-10 2007-05-23 Wyeth a Corporation of the State of Delaware Process for the scalable synthesis of 1, 3, 4, 9-tetrahydropyranoý3, 4-b¨-indole derivatives
US20070185346A1 (en) * 2006-02-03 2007-08-09 Vaidya Niteen A Kit for automated resolving agent selection and method thereof
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
CN102834097B (zh) * 2009-12-23 2015-06-17 艾科尔公司 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
CN104379144A (zh) * 2012-04-23 2015-02-25 艾科尔公司 高度纯的吡咯并喹啉基-吡咯-2,5-二酮和吡咯并喹啉基-吡咯烷-2,5-二酮及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229026A1 (en) * 1999-12-16 2003-12-11 Al-Awar Rima Salim Agents and methods for the treatment of proliferative diseases
JP2008530026A (ja) * 2005-02-09 2008-08-07 アーキュール，インコーポレーテッド マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
JP2010530884A (ja) * 2007-06-22 2010-09-16 アークル インコーポレイテッド 癌の治療のための組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5011005432; ＣＡＩＲＡ　Ｍ　Ｒ: 'ＣＲＹＳＴＡＬＬＩＮＥ　ＰＯＬＹＭＯＲＰＨＩＳＭ　ＯＦ　ＯＲＧＡＮＩＣ　ＣＯＭＰＯＵＮＤＳ' ＴＯＰＩＣＳ　ＩＮ　ＣＵＲＲＥＮＴ　ＣＨＥＭＩＳＴＲＹ Ｖ１９８, 19980101, Ｐ１６３-２０８, ＳＰＲＩＮＧＥＲ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016041712A (ja) * 2009-12-23 2016-03-31 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
JP2014518284A (ja) * 2011-07-07 2014-07-28 アーキュール，インコーポレイティド ピロロキノリニル−ピロリジン−２，５−ジオン製剤及びその調製方法及び使用方法
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
JP2020530497A (ja) * 2017-08-11 2020-10-22 アクチュエイト セラピューティクス インク． ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態
JP2023156372A (ja) * 2017-08-11 2023-10-24 アクチュエイト セラピューティクス インク． ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
JP7424639B2 (ja) 2017-08-11 2024-01-30 アクチュエイト セラピューティクス インク． ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態
US12145943B2 (en) 2017-08-11 2024-11-19 Actuate Therapeutics Inc. Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
JP7778750B2 (ja) 2017-08-11 2025-12-02 アクチュエイト セラピューティクス インク． ３－（５－フルオロベンゾフラン－３－イル）－４－（５－メチル－５Ｈ－［１，３］ジオキソロ［４，５－ｆ］インドール－７－イル）ピロール－２，５－ジオンの固体形態

Also Published As

Publication number Publication date
NZ628087A (en) 2016-02-26
CO6561823A2 (es) 2012-11-15
EP3081567A3 (en) 2016-11-16
WO2011079142A2 (en) 2011-06-30
PH12012501293A1 (en) 2013-01-07
BR112012015656A2 (pt) 2016-05-10
MY169232A (en) 2019-03-19
RU2012131344A (ru) 2014-01-27
US8871933B2 (en) 2014-10-28
KR20160121602A (ko) 2016-10-19
US8552192B2 (en) 2013-10-08
JP2016041712A (ja) 2016-03-31
CA2785503A1 (en) 2011-06-30
TWI506026B (zh) 2015-11-01
ZA201204759B (en) 2014-03-26
US20140031551A1 (en) 2014-01-30
TW201141865A (en) 2011-12-01
AU2015243015B2 (en) 2017-02-02
WO2011079142A3 (en) 2011-11-24
EP3081567A2 (en) 2016-10-19
MY156701A (en) 2016-03-15
CN104910159A (zh) 2015-09-16
HK1215025A1 (zh) 2016-08-12
AU2010336533B2 (en) 2015-09-10
US9499540B2 (en) 2016-11-22
EP2515904A2 (en) 2012-10-31
US20160024076A1 (en) 2016-01-28
RU2556205C2 (ru) 2015-07-10
TW201542546A (zh) 2015-11-16
AU2010336533B9 (en) 2015-10-08
NZ600800A (en) 2014-10-31
EP2515904A4 (en) 2013-07-03
CN102834097B (zh) 2015-06-17
KR101669707B1 (ko) 2016-10-27
MX2012007259A (es) 2015-05-15
AU2015243015A1 (en) 2015-11-05
AU2010336533A1 (en) 2012-07-12
SG181927A1 (en) 2012-07-30
PH12014500310A1 (en) 2015-09-28
TWI557125B (zh) 2016-11-11
US20110160242A1 (en) 2011-06-30
TW201643163A (zh) 2016-12-16
CN102834097A (zh) 2012-12-19
KR20120113760A (ko) 2012-10-15

Similar Documents

Publication Publication Date Title
JP2016041712A (ja) 精製されたピロロキノリニル−ピロリジン−２，５−ジオン組成物ならびにその調製方法および使用方法
EP2836216B1 (en) Combination therapy for treating cancer
JP4171061B2 (ja) マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
US9597341B2 (en) Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
EP3793993A1 (en) Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
JP2021504332A (ja) ピラゾロピリジノン化合物
WO2022111644A1 (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
TW202016114A (zh) 抑制ｃｄｋ４／６活性化合物的晶型及其應用
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
CN104884456B (zh) PI3K和/或mTOR抑制剂
TW202102487A (zh) N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170104